Epigral enters epoxy resins with two Dahej plants, capex undisclosed
Board approves a 125,000 TPA epoxy resin plant and a multi-purpose unit, both to be commissioned by H2FY28. The investment amount is not disclosed, leaving scale unmeasured.
— 3 earlier stories on Epigral Ltd. →What's new
- Board cleared two greenfield projects at Dahej: an epoxy resin plant and a multi-purpose intermediate facility.
- Epoxy resin (125K TPA) is a new product line, targeting renewable energy, electronics, and infrastructure.
- No investment amount was disclosed, limiting assessment of financial impact.
Why this matters
Epigral is pushing deeper into downstream specialty chemicals with a new epoxy resin stream in a high-growth market. But without a capex figure, investors can't gauge whether the spend is modest relative to its ₹4,772 cr market cap or a stretch on its 0.25 debt/equity ratio.
What we're watching
- Disclosure of the total investment in future filings - the missing piece for return analysis.
- Execution progress toward H2FY28 commissioning; any delays could signal cost overruns.
- Debt/equity movement - currently low, the capex could raise it meaningfully.
The full read
Epigral is making its biggest strategic move in years: a 125,000 TPA epoxy resin plant and a multi-purpose intermediate facility, both at Dahej and due online in H2FY28. Epoxy resin is a new product line for the company, opening a door into renewable-energy, electronics, and infrastructure supply chains that command higher margins than basic commodities. The multi-purpose plant deepens backward integration, consuming inputs from Epigral's own epichlorohydrin and chlorotoluene lines. The quarterly numbers (₹709 cr revenue, 25% EBITDA margin) were routine. What matters now is the missing capex figure. Without it, the market can't weigh the scale of the spend against a ₹4,772 cr market cap and a 0.25 debt/equity ratio. The intent is clear; the price tag isn't.
Questions answered
- Why is the undisclosed capex a concern?
- Without the investment amount, analysts cannot calculate return on capital or assess the impact on free cash flow and leverage. It's a gap that limits the market's ability to price the expansion.
- What will the multi-purpose plant produce?
- The multi-purpose facility will produce intermediates for pharmaceuticals, agrochemicals, and water treatment, using raw materials from Epigral's existing epichlorohydrin and chlorotoluene value chains.
- When do the plants start production?
- Both plants are expected to begin production in the second half of the fiscal year ending March 2028, i.e., H2FY28.
- How did Epigral perform in Q1 FY27?
- Quarterly revenue rose 15% to ₹709 crore with an EBITDA margin of 25%, broadly in line with guidance. The numbers do not materially alter near-term earnings expectations.
- What markets does the epoxy resin plant target?
- The plant targets both domestic and global demand in renewable energy, electronics, and infrastructure sectors - high-growth end markets.
Story so far
All notes on EPIGRAL →- 27 Jul 2026 · 2:18 PM IST Epigral enters epoxy resins with two Dahej plants, capex undisclosed
- today Epigral bets ₹600 cr on epoxy resins in strategic pivot
- today Epigral Q1: Revenue up 16%, adjusted PAT jumps 24%
- today Epigral logs 16% revenue growth in Q1; PAT falls on one-time credit base effect